BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Fred Cohen Nominated to BioCryst’s Board’s List


Dallas, Texas 07/24/2013 (Financialstrend) – BioCryst Pharmaceuticals, Inc., (NASDAQ:BCRX) today made declaration that Fred E. Cohen, managing director, D.Phil., got elected to the firm’s board.

George B. Abercrombie, Chairman of the panel of BioCryst stated, “The Company’s directors and Leadership group of BioCryst are very happy to have Cohen become part of the firm’s Board.”

“Cohen brings a wealth of technical awareness and biz insight to the firm and has been a priceless resource to the group for many years as both a consultant and as a shareholder. We anticipate his leadership and insights in the direction of the further triumph of the company.”

In the year 2001, Dr. Fred got connected to TPG to begin TPG’s project attempts in bioengineering and biosciences, and he acts as a Partner and MD at TPG Biotech.

Dr. Fred has been an associate of the staff of University of California, San Francisco (UCSF) since the year 1986.

At UCSF, Dr. Fred has worked as an Internist for hospitalized people, a consulting medical specialist and as the head of the section of Endocrinology and Metabolism.

His study interests consist of structure based medicine design, prion illnesses, computational environmental science and heteropolymer chemical science. Fred’s investigation is best acknowledged in the arenas of protein arrangement and the configuration basis of prion ailment.

At present Dr. Fred is a part of the Board of Directors of Genomic Health, Quintiles Transnational and the panels of a number of privately held firms.

“Both peramivir as well as BCX4161 got detected utilizing structure based medicine design, an established approach to formulating strong and choosy inhibitors of accelerators involved in illness,” added up Dr. Fred. “With the current development in BioCryst’s inherited angioedema and peramivir flu growth plans, it is an exhilarating time to become part of its Board of Directors.”

BioCryst Pharmaceuticals, Inc. announced the outcome of stage 1 BCX4161 clinical trial, which is used for the cure of inherited Angioedema.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.